KIR receptor‐ligand incompatibility predicts killing of osteosarcoma cell lines by allogeneic NK cells

The effectiveness of killer immunoglobulin‐like receptor (KIR) incompatible, alloreactive natural killer (NK) cells has been primarily documented in hematological malignancies following stem‐cell transplant. This effect has not been thoroughly evaluated for pediatric solid tumors. In this study, we evaluated KIR receptor‐ligand incompatibility of NK cells against osteosarcoma cell lines.

[1]  J. Vicario,et al.  KIR–HLA receptor‐ligand mismatch associated with a graft‐versus‐tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors , 2009, Pediatric blood & cancer.

[2]  R. Handgretinger,et al.  Inhibitory KIR–HLA receptor–ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma , 2007, British Journal of Cancer.

[3]  Zhengjia Chen,et al.  Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Pandha,et al.  Loss of expression of antigen‐presenting molecules in human pancreatic cancer and pancreatic cancer cell lines , 2007, Clinical and experimental immunology.

[5]  F. Garrido,et al.  Different mechanisms can lead to the same altered HLA class I phenotype in tumors. , 2007, Tissue antigens.

[6]  T. Yamashita,et al.  Prognostic significance of HLA class I expression in osteosarcoma defined by anti‐pan HLA class I monoclonal antibody, EMR8‐5 , 2006, Cancer science.

[7]  M. Martelli,et al.  Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation. , 2006, Seminars in cancer biology.

[8]  F. Re,et al.  Killer cell Ig‐like receptors ligand‐mismatched, alloreactive natural killer cells lyse primary solid tumors , 2006, Cancer.

[9]  K. Goi,et al.  A successful case of allogeneic bone marrow transplantation for osteosarcoma with multiple metastases of lung and bone , 2006, Bone Marrow Transplantation.

[10]  F. Behm,et al.  Comparison of Killer Ig-Like Receptor Genotyping and Phenotyping for Selection of Allogeneic Blood Stem Cell Donors1 , 2005, The Journal of Immunology.

[11]  F. Garrido,et al.  Coordinated downregulation of the antigen presentation machinery and HLA class I/β2‐microglobulin complex is responsible for HLA‐ABC loss in bladder cancer , 2005, International journal of cancer.

[12]  J. P. McCoy,et al.  Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. , 2004, Blood.

[13]  R. Handgretinger,et al.  Determinants of Antileukemia Effects of Allogeneic NK Cells 1 , 2004, The Journal of Immunology.

[14]  F. Garrido,et al.  Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. , 2003, Tissue antigens.

[15]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[16]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[17]  A. Tosti,et al.  Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. , 1999, Blood.

[18]  Eric O Long,et al.  Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. , 1998, Journal of immunology.

[19]  C. Figdor,et al.  Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. , 1998, Journal of immunology.

[20]  P. Pizzo,et al.  Principles and Practice of Pediatric Oncology , 1989 .